RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eiger BioPharmaceuticals Stock

Eiger BioPharmaceuticals Debt 2024

Eiger BioPharmaceuticals Debt

15.68 USD

Ticker

EIGR

ISIN

US28249U1051

WKN

A2AF9X

In 2024, Eiger BioPharmaceuticals's total debt was 15.68 USD, a 13.62% change from the 13.8 USD total debt recorded in the previous year.

Eiger BioPharmaceuticals Aktienanalyse

What does Eiger BioPharmaceuticals do?

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Eiger BioPharmaceuticals's Debt Structure

Eiger BioPharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Eiger BioPharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Eiger BioPharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Eiger BioPharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Eiger BioPharmaceuticals stock

What is the debt of Eiger BioPharmaceuticals this year?

Eiger BioPharmaceuticals has a debt level of 15.68 USD this year.

What was the debt of Eiger BioPharmaceuticals compared to the previous year?

The debt of Eiger BioPharmaceuticals has increased by 13.62% compared to the previous year increased.

What are the consequences of high debt for investors in Eiger BioPharmaceuticals?

High debt can pose a risk for investors of Eiger BioPharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Eiger BioPharmaceuticals?

Low debt means that Eiger BioPharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Eiger BioPharmaceuticals affect the company?

An increase in debt of Eiger BioPharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Eiger BioPharmaceuticals affect the company?

A reduction in debt of Eiger BioPharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Eiger BioPharmaceuticals?

Some factors that can influence the debt of Eiger BioPharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Eiger BioPharmaceuticals so important for investors?

The debts of Eiger BioPharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Eiger BioPharmaceuticals take to change the debt?

To change the debt, Eiger BioPharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eiger BioPharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.